Literature DB >> 28076836

The metabolic syndrome and 10-year cognitive and functional decline in very old men. A population-based study.

Giovanni Viscogliosi1, Chiara Donfrancesco2, Luigi Palmieri2, Simona Giampaoli2.   

Abstract

OBJECTIVES: To describe longitudinal relationships of metabolic syndrome (MetS) to cognitive decline and functional disability in a sample of older non-institutionalized men.
METHODS: data from 1991 to 2000 of the Italian cohorts of the Finland, Italy, the Netherlands, Elderly (FINE) study, were used. Global cognitive function and functional disability, defined as limitations in mobility, basic (ADLs) and instrumental activities of daily living (IADLs) were screened in 1991 and 2000. MetS was defined according to the NCEP ATP-III criteria.
RESULTS: The study sample consisted of 195 men, baseline age 76.1±3.1years. Baseline MetS was prospectively associated with greater 10-year cognitive and functional decline in ADLs and IADLs. After multiple adjustment including age, education, marital status, ApoE ε4 allele, cerebrovascular disease and initial cognitive and depressive status, MetS predicted cognitive decline (B=-1.684, 95%CI=-2.202 to -1.167, p<0.001) and risk of IADLs (OR=1.09, 95% CI=1.01-1.20, p=0.048) and ADLs disability (OR=1.35, 95%CI=1.12-1.62, p<0.001). Interestingly, such associations were not attributable to individual altered components of MetS nor to their sum. Incident disability in ADLs and IADLs were not explained by parallel decline in cognitive function.
CONCLUSIONS: MetS as an entity was associated with accelerated cognitive and functional decline in a population-based sample of very old men.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cognitive decline; Functional disability; Incidence; Metabolic syndrome

Mesh:

Year:  2017        PMID: 28076836     DOI: 10.1016/j.archger.2016.12.008

Source DB:  PubMed          Journal:  Arch Gerontol Geriatr        ISSN: 0167-4943            Impact factor:   3.250


  7 in total

1.  Metabolic syndrome predicts incident disability and functional decline among Chinese older adults: results from the China Health and Retirement Longitudinal Study.

Authors:  Quan Zhang; Yi Wang; Nan Yu; Hua Ding; Danyu Li; Xinyi Zhao
Journal:  Aging Clin Exp Res       Date:  2021-03-20       Impact factor: 3.636

2.  Metabolic Syndrome and Physical Performance: The Moderating Role of Cognition among Middle-to-Older-Aged Adults.

Authors:  Elisa F Ogawa; Elizabeth Leritz; Regina McGlinchey; William Milberg; Jonathan F Bean
Journal:  J Int Neuropsychol Soc       Date:  2020-08-10       Impact factor: 2.892

Review 3.  Metabolic Syndrome and cognitive decline in the elderly: A systematic review.

Authors:  Naima Assuncao; Felipe Kenji Sudo; Claudia Drummond; Fernanda Guarino de Felice; Paulo Mattos
Journal:  PLoS One       Date:  2018-03-26       Impact factor: 3.240

4.  Sex differences in the relationship between cognitive impairment and overweight or obesity in late life: A 3-year prospective study.

Authors:  Hye-Mi Noh; Junhee Han; Yeo Jin Kim; Jin-Hyung Jung; Yong Kyun Roh; Hong Ji Song
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

5.  Vascular mild cognitive impairment and its relationship to hemoglobin A1c levels and apolipoprotein E genotypes in the Dominican Republic.

Authors:  Martin Medrano; Gelanys Castro-Tejada; Rafael Lantigua; Gretel Silvestre; Sergio Diaz; Patricia Mota; Franck Diaz-Garelli
Journal:  Dement Neuropsychol       Date:  2021 Jan-Mar

6.  The association between metabolic syndrome and successful aging- using an extended definition of successful aging.

Authors:  Yi-Hsuan Lin; Jeng-Min Chiou; Ta-Fu Chen; Liang-Chuan Lai; Jen-Hau Chen; Yen-Ching Chen
Journal:  PLoS One       Date:  2021-11-30       Impact factor: 3.240

Review 7.  Role of Helicobacter pylori infection in the manifestation of old age-related diseases.

Authors:  Abolfazl Zendehdel; Maryam Roham
Journal:  Mol Genet Genomic Med       Date:  2020-02-17       Impact factor: 2.183

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.